

## **Medicine summary - Antipsychotics- carbamazepine**

		Case Group	Death Outcomes	Sole
Case Count		<b>2408</b>	<b>38</b>	<b>1446</b>
Reaction Count	Blood and lymphatic system disorders	Anaemia	9	0
		Aplastic anaemia	6	3
		Bone marrow failure	8	0
		Hypoplastic anaemia	2	0
		Pancytopenia	22	3
		Coagulopathy	4	0
		Disseminated intravascular coagulation	1	0
		Coombs positive haemolytic anaemia	4	0
		Thrombocytopenia	85	3
		Thrombocytopenia neonatal	1	0
		Thrombocytopenic purpura	1	0
		Thrombocytosis	1	0
		Lymphadenitis	1	0
		Lymphadenopathy	68	0
		Necrotising granulomatous lymphadenitis	1	0
		Splenomegaly	8	0
		Eosinophilia	49	0
		Leukocytosis	6	1
		Lymphocytosis	6	0
		Monocytosis	1	0
		Leukopenia	38	0
		Lymphopenia	15	0
		Agranulocytosis	27	3
		Neutropenia	76	2
		<b>Blood and lymphatic system disorders</b>	<b>440</b>	<b>15</b>
				<b>259</b>
Cardiac disorders	Cardiac disorders	Atrioventricular block	4	0
		Bundle branch block	1	0
		Arrhythmia	3	2
		Bradycardia	8	0
		Extrasystoles	1	0
		Nodal arrhythmia	1	0
		Tachycardia	8	0

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## Medicine summary - Antipsychotics- carbamazepine

			Case Group	Death Outcomes	Sole
Reaction Count	Cardiac disorders	Atrial fibrillation	3	0	3
		Supraventricular tachycardia	1	0	1
		Cardiac arrest	4	3	1
		Ventricular tachycardia	2	1	0
		Cyanosis	4	1	3
		Palpitations	5	0	3
		Aortic valve stenosis	1	0	0
		Tricuspid valve incompetence	1	0	1
		Angina pectoris	2	0	1
		Myocardial infarction	2	0	1
		Cardiac failure	2	1	0
		Cardiac failure congestive	2	0	2
		Right ventricular failure	1	0	0
		Cardiomegaly	1	0	0
		Left ventricular hypertrophy	1	0	1
		Myocarditis	3	1	2
		Pericarditis	2	0	2
		<b>Cardiac disorders</b>	<b>63</b>	<b>9</b>	<b>37</b>
	Congenital, familial and genetic disorders	Congenital arterial malformation	1	0	1
		Pulmonary artery stenosis congenital	1	0	0
		Heart disease congenital	4	1	0
		Ventricular septal defect	2	0	1
		Ebstein's anomaly	1	0	1
		Congenital anomaly	1	0	0
		Foetal malformation	1	0	0
		Multiple congenital abnormalities	6	0	1
		Congenital eye disorder	1	0	0
		Pyloric stenosis	1	0	1
		Exomphalos	1	0	0
		Cleft palate	4	0	0
		Congenital jaw malformation	1	0	0
		Congenital hand malformation	4	0	1
		Microcephaly	3	0	1

## Outcome Description

 (Causality possible,Causality probable,Causality certain)

 Suspect Type

## Suspect Code

## Case Group

 GM

## Carbamazepine

## **Medicine summary - Antipsychotics- carbamazepine**

Case Group	Death Outcomes	Sole	
Skull malformation	<b>1</b>	<b>0</b>	<b>1</b>
Spine malformation	<b>1</b>	<b>0</b>	<b>0</b>
Congenital musculoskeletal anomaly	<b>3</b>	<b>0</b>	<b>2</b>
Dysmorphism	<b>1</b>	<b>0</b>	<b>1</b>
Meningomyelocele	<b>3</b>	<b>0</b>	<b>0</b>
Spina bifida	<b>6</b>	<b>1</b>	<b>1</b>
Congenital brain damage	<b>1</b>	<b>0</b>	<b>0</b>
Congenital hydrocephalus	<b>6</b>	<b>0</b>	<b>1</b>
Urinary tract malformation	<b>1</b>	<b>0</b>	<b>1</b>
Renal aplasia	<b>1</b>	<b>0</b>	<b>1</b>
Kidney duplex	<b>1</b>	<b>0</b>	<b>0</b>
Hypospadias	<b>2</b>	<b>0</b>	<b>0</b>
Tracheo-oesophageal fistula	<b>1</b>	<b>0</b>	<b>1</b>
Pulmonary malformation	<b>1</b>	<b>1</b>	<b>1</b>
Congenital nail disorder	<b>2</b>	<b>0</b>	<b>1</b>
<b>Congenital, familial and genetic disorders</b>	<b>63</b>	<b>3</b>	<b>18</b>
Ear and labyrinth disorders			
Otorrhoea	<b>1</b>	<b>0</b>	<b>1</b>
Deafness	<b>5</b>	<b>0</b>	<b>3</b>
Hearing impaired	<b>2</b>	<b>0</b>	<b>2</b>
Tinnitus	<b>8</b>	<b>0</b>	<b>5</b>
Vertigo	<b>16</b>	<b>0</b>	<b>10</b>
<b>Ear and labyrinth disorders</b>	<b>32</b>	<b>0</b>	<b>21</b>
Endocrine disorders			
Adrenal insufficiency	<b>1</b>	<b>1</b>	<b>0</b>
Inappropriate antidiuretic hormone secretion	<b>32</b>	<b>1</b>	<b>19</b>
Hyperparathyroidism	<b>1</b>	<b>0</b>	<b>1</b>
Hypothyroidism	<b>1</b>	<b>0</b>	<b>0</b>
<b>Endocrine disorders</b>	<b>35</b>	<b>2</b>	<b>20</b>
Eye disorders			
Cataract	<b>1</b>	<b>0</b>	<b>0</b>
Dry eye	<b>1</b>	<b>0</b>	<b>1</b>
Lacrimal disorder	<b>1</b>	<b>0</b>	<b>1</b>
Eye pain	<b>5</b>	<b>0</b>	<b>4</b>
Eye swelling	<b>1</b>	<b>0</b>	<b>0</b>
Periorbital oedema	<b>15</b>	<b>0</b>	<b>12</b>

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Case Group	Death Outcomes	Sole
Glaucoma	4	0
Conjunctival hyperaemia	1	0
Conjunctival ulcer	1	0
Conjunctivitis	32	0
Keratitis	1	0
Ulcerative keratitis	2	0
Uveitis	1	0
Eyelid oedema	2	0
Eye pruritus	1	0
Ocular hyperaemia	2	0
Scleritis	1	0
Blepharospasm	1	0
Eyelid ptosis	1	0
Eye movement disorder	1	0
Oculogyric crisis	1	0
Pupillary reflex impaired	1	0
Photophobia	10	0
Papilloedema	1	0
Visual acuity reduced	1	0
Accommodation disorder	1	0
Diplopia	25	0
Vision blurred	10	0
Visual impairment	22	0
<b>Eye disorders</b>	<b>147</b>	<b>0</b>
	<b>99</b>	
Tooth discolouration	1	0
Gingival hyperplasia	1	0
Gingivitis	1	0
Gingival bleeding	3	0
Pancreatitis	3	1
Gastrointestinal disorder	1	0
Rectal haemorrhage	4	0
Haematemesis	6	0
Melaena	2	0

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Reaction Count			Case Group	Death Outcomes	Sole
	Gastrointestinal disorders	Colitis	2	0	2
		Colitis ulcerative	1	0	1
		Gastritis	4	0	2
		Gastritis haemorrhagic	1	1	0
		Enteritis	1	0	1
		Oesophagitis	2	0	1
		Proctitis	1	0	1
		Diarrhoea	52	0	38
		Constipation	12	0	8
		Gastrooesophageal reflux disease	1	0	1
		Irritable bowel syndrome	1	0	1
		Dyspepsia	7	0	4
		Eruption	3	0	3
		Faeces discoloured	1	0	1
		Faeces pale	1	0	1
		Abdominal distension	3	1	2
		Abdominal pain	39	0	28
		Abdominal pain upper	5	0	5
		Abdominal rigidity	1	0	1
		Abdominal discomfort	1	0	1
		Dysphagia	10	0	7
		Aphagia	1	0	1
		Nausea	156	1	91
		Vomiting	128	2	74
		Duodenal ulcer	1	0	0
		Oesophagitis ulcerative	1	0	0
		Cheilitis	1	0	0
		Lip blister	2	0	1
		Lip swelling	6	0	5
		Lip haemorrhage	1	0	1
		Mouth haemorrhage	2	0	2
		Lip pain	1	0	1
		Oral pain	1	0	1

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Reaction Count			Case Group	Death Outcomes	Sole
	Gastrointestinal disorders	Lip discolouration	1	0	1
		Oedema mouth	2	0	2
		Aphthous stomatitis	2	0	2
		Mouth ulceration	41	0	33
		Stomatitis	6	0	3
		Ascites	2	0	0
		Dry mouth	14	0	8
		Salivary hypersecretion	2	0	2
		Salivary gland enlargement	1	0	0
		Glossitis	3	0	1
		Tongue disorder	1	0	0
		Tongue ulceration	1	0	1
		Swollen tongue	3	0	3
		Tongue discolouration	1	0	0
		Tongue oedema	9	0	7
		<b>Gastrointestinal disorders</b>	<b>561</b>	<b>6</b>	<b>360</b>
	General disorders and administration site conditions	Hypothermia	2	0	0
		Pyrexia	<b>308</b>	2	<b>218</b>
		Death	1	1	0
		Death neonatal	2	0	0
		Sudden death	11	11	1
		Asthenia	23	0	16
		Fatigue	72	0	50
		Malaise	86	0	61
		Gait disturbance	14	0	8
		Condition aggravated	3	0	1
		Influenza like illness	7	0	6
		Irritability	1	0	0
		Multi-organ failure	1	0	0
		Swelling	1	0	1
		Hernia	2	0	1
		Inflammation	2	0	2
		Enanthema	2	0	2

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Case Group	Death Outcomes	Sole	
Mucosal inflammation	<b>6</b>	<b>0</b>	<b>4</b>
Mucosal ulceration	<b>1</b>	<b>0</b>	<b>1</b>
Face oedema	<b>42</b>	<b>0</b>	<b>29</b>
Generalised oedema	<b>5</b>	<b>0</b>	<b>4</b>
Gravitational oedema	<b>7</b>	<b>0</b>	<b>3</b>
Localised oedema	<b>2</b>	<b>0</b>	<b>1</b>
Oedema	<b>14</b>	<b>0</b>	<b>10</b>
Oedema peripheral	<b>23</b>	<b>0</b>	<b>14</b>
Chest pain	<b>8</b>	<b>0</b>	<b>6</b>
Facial pain	<b>1</b>	<b>0</b>	<b>1</b>
Pain	<b>16</b>	<b>0</b>	<b>11</b>
Chest discomfort	<b>1</b>	<b>0</b>	<b>1</b>
Chills	<b>74</b>	<b>0</b>	<b>54</b>
Feeling abnormal	<b>3</b>	<b>0</b>	<b>1</b>
Feeling drunk	<b>1</b>	<b>0</b>	<b>0</b>
Feeling hot	<b>1</b>	<b>0</b>	<b>1</b>
Thirst	<b>2</b>	<b>0</b>	<b>1</b>
Drug interaction	<b>43</b>	<b>0</b>	<b>1</b>
Drug effect decreased	<b>1</b>	<b>0</b>	<b>0</b>
Drug ineffective	<b>47</b>	<b>2</b>	<b>25</b>
Therapeutic response decreased	<b>10</b>	<b>0</b>	<b>6</b>
Therapeutic response unexpected	<b>1</b>	<b>0</b>	<b>1</b>
Drug withdrawal syndrome	<b>3</b>	<b>0</b>	<b>2</b>
Impaired healing	<b>1</b>	<b>0</b>	<b>0</b>
Fat necrosis	<b>1</b>	<b>0</b>	<b>0</b>
Ulcer	<b>1</b>	<b>0</b>	<b>1</b>
Incorrect product storage	<b>1</b>	<b>0</b>	<b>1</b>
Product formulation issue	<b>1</b>	<b>0</b>	<b>1</b>
Product quality issue	<b>1</b>	<b>0</b>	<b>1</b>
<b>General disorders and administration site conditions</b>	<b>856</b>	<b>16</b>	<b>548</b>
Hepatobiliary disorders			
Cholangitis	<b>1</b>	<b>0</b>	<b>0</b>
Vanishing bile duct syndrome	<b>1</b>	<b>0</b>	<b>1</b>

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Reaction Count			Case Group	Death Outcomes	Sole
	Hepatobiliary disorders	Cholestasis	1	0	1
		Hepatitis cholestatic	23	0	14
		Jaundice	37	1	25
		Liver injury	4	0	3
		Hepatic function abnormal	204	2	133
		Hepatic failure	10	2	0
		Hepatic cirrhosis	1	0	0
		Hepatomegaly	20	0	14
		Hepatosplenomegaly	4	0	3
		Autoimmune hepatitis	1	0	0
		Granulomatous liver disease	1	0	1
		Hepatic necrosis	3	3	0
		Hepatitis	88	2	58
		Hepatitis acute	1	0	1
		Hepatocellular injury	6	0	3
		Hepatotoxicity	1	0	1
		<b>Hepatobiliary disorders</b>	<b>407</b>	<b>10</b>	<b>258</b>
	Immune system disorders	Hypersensitivity	14	1	11
		Serum sickness	1	0	1
		<b>Immune system disorders</b>	<b>15</b>	<b>1</b>	<b>12</b>
	Infections and infestations	Staphylococcal infection	1	0	0
		Candidiasis	2	0	1
		Breast abscess	1	0	1
		Meningitis	2	1	1
		Hordeolum	1	0	1
		Vaginal infection	1	0	1
		Infection	1	0	1
		Purulent discharge	1	0	1
		Bronchitis	1	0	1
		Pneumonia	10	1	5
		Sepsis	4	1	0
		Rash pustular	5	0	3
		Nasopharyngitis	1	0	0

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

			Case Group	Death Outcomes	Sole
Reaction Count	Infections and infestations	Pharyngitis	23	0	15
		Rhinitis	3	0	0
		Tonsillitis	1	0	1
		Upper respiratory tract infection	1	0	1
		Herpes simplex	1	0	1
		Herpes zoster	1	0	0
		Genital herpes	1	0	0
		<b>Infections and infestations</b>	<b>62</b>	<b>3</b>	<b>34</b>
	Injury, poisoning and procedural complications	Accidental poisoning	1	1	0
		Toxicity to various agents	11	4	2
		Drug exposure during pregnancy	12	1	4
		Subdural haematoma	1	1	0
		Fall	9	0	4
		Head injury	1	0	1
		Contusion	2	0	2
		Laceration	1	0	0
		Inappropriate schedule of drug administration	1	0	0
		Wrong technique in drug usage process	1	0	1
		Drug dispensing error	1	0	1
		Medication error	2	0	2
		Accidental exposure	1	0	1
		Overdose	3	2	1
		<b>Injury, poisoning and procedural complications</b>	<b>47</b>	<b>9</b>	<b>19</b>
	Investigations	Electrocardiogram abnormal	1	0	0
		Heart rate decreased	1	0	1
		Heart rate increased	1	0	0
		Heart rate irregular	1	0	0
		Blood pressure increased	2	0	1
		Cytogenetic analysis abnormal	1	0	0
		Cortisol free urine increased	1	0	1
		Blood prolactin increased	1	0	1
		Pregnancy test urine positive	1	0	0

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Reaction Count	Investigations	Case Group	Death Outcomes	Sole
	Thyroid function test abnormal	<b>1</b>	<b>0</b>	<b>1</b>
	Blood creatine phosphokinase increased	<b>7</b>	<b>0</b>	<b>2</b>
	Troponin I increased	<b>1</b>	<b>0</b>	<b>0</b>
	Troponin increased	<b>1</b>	<b>0</b>	<b>0</b>
	Blood alkaline phosphatase increased	<b>5</b>	<b>0</b>	<b>2</b>
	Blood lactate dehydrogenase increased	<b>1</b>	<b>0</b>	<b>1</b>
	International normalised ratio decreased	<b>1</b>	<b>0</b>	<b>1</b>
	International normalised ratio increased	<b>3</b>	<b>0</b>	<b>1</b>
	Prothrombin level decreased	<b>2</b>	<b>1</b>	<b>1</b>
	Prothrombin level increased	<b>1</b>	<b>0</b>	<b>0</b>
	Red blood cell sedimentation rate increased	<b>10</b>	<b>0</b>	<b>6</b>
	Platelet count decreased	<b>1</b>	<b>0</b>	<b>1</b>
	Platelet count increased	<b>1</b>	<b>0</b>	<b>1</b>
	Haemoglobin decreased	<b>1</b>	<b>0</b>	<b>0</b>
	White blood cell count decreased	<b>1</b>	<b>0</b>	<b>1</b>
	Alanine aminotransferase increased	<b>4</b>	<b>0</b>	<b>1</b>
	Aspartate aminotransferase increased	<b>2</b>	<b>0</b>	<b>1</b>
	Gamma-glutamyltransferase increased	<b>9</b>	<b>0</b>	<b>5</b>
	Hepatic enzyme increased	<b>3</b>	<b>0</b>	<b>3</b>
	Liver function test abnormal	<b>27</b>	<b>0</b>	<b>24</b>
	Antinuclear antibody positive	<b>1</b>	<b>0</b>	<b>0</b>
	Blood cholesterol increased	<b>3</b>	<b>0</b>	<b>2</b>
	Carnitine decreased	<b>2</b>	<b>0</b>	<b>0</b>
	Blood triglycerides increased	<b>3</b>	<b>0</b>	<b>2</b>
	Blood folate abnormal	<b>1</b>	<b>0</b>	<b>0</b>
	Nuclear magnetic resonance imaging brain abnormal	<b>1</b>	<b>0</b>	<b>1</b>
	Electroencephalogram abnormal	<b>1</b>	<b>0</b>	<b>0</b>
	Intraocular pressure increased	<b>1</b>	<b>0</b>	<b>1</b>
	Weight decreased	<b>15</b>	<b>0</b>	<b>8</b>
	Weight increased	<b>10</b>	<b>0</b>	<b>7</b>
	C-reactive protein increased	<b>5</b>	<b>0</b>	<b>3</b>
	Globulins decreased	<b>1</b>	<b>0</b>	<b>1</b>
	Blood creatinine increased	<b>2</b>	<b>0</b>	<b>0</b>

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Case Group	Death Outcomes	Sole	
Urine analysis abnormal	<b>8</b>	<b>0</b>	<b>8</b>
Urine colour abnormal	<b>3</b>	<b>0</b>	<b>3</b>
Anticonvulsant drug level increased	<b>2</b>	<b>0</b>	<b>1</b>
Drug level above therapeutic	<b>3</b>	<b>0</b>	<b>3</b>
Drug level changed	<b>1</b>	<b>0</b>	<b>0</b>
Drug level decreased	<b>13</b>	<b>0</b>	<b>2</b>
Drug level increased	<b>55</b>	<b>0</b>	<b>18</b>
Blood calcium decreased	<b>1</b>	<b>0</b>	<b>0</b>
Blood sodium decreased	<b>2</b>	<b>0</b>	<b>2</b>
Blood osmolarity decreased	<b>1</b>	<b>0</b>	<b>0</b>
<b>Investigations</b>	<b>227</b>	<b>1</b>	<b>118</b>
Metabolism and nutrition disorders			
Metabolic acidosis	<b>1</b>	<b>0</b>	<b>0</b>
Alkalosis	<b>1</b>	<b>0</b>	<b>1</b>
Acidosis	<b>1</b>	<b>0</b>	<b>1</b>
Decreased appetite	<b>45</b>	<b>0</b>	<b>30</b>
Hypophagia	<b>1</b>	<b>0</b>	<b>0</b>
Increased appetite	<b>1</b>	<b>0</b>	<b>1</b>
Feeding disorder neonatal	<b>1</b>	<b>0</b>	<b>1</b>
Hypercalcaemia	<b>1</b>	<b>0</b>	<b>0</b>
Hypocalcaemia	<b>6</b>	<b>1</b>	<b>4</b>
Tetany	<b>1</b>	<b>0</b>	<b>0</b>
Hypomagnesaemia	<b>3</b>	<b>1</b>	<b>2</b>
Hypochloraemia	<b>5</b>	<b>0</b>	<b>5</b>
Polydipsia	<b>5</b>	<b>0</b>	<b>3</b>
Hyperkalaemia	<b>5</b>	<b>1</b>	<b>2</b>
Hypokalaemia	<b>15</b>	<b>1</b>	<b>7</b>
Hyponatraemia	<b>174</b>	<b>2</b>	<b>92</b>
Dehydration	<b>7</b>	<b>0</b>	<b>3</b>
Hypovolaemia	<b>1</b>	<b>0</b>	<b>0</b>
Fluid retention	<b>2</b>	<b>0</b>	<b>2</b>
Alcohol intolerance	<b>1</b>	<b>0</b>	<b>0</b>
Diabetes mellitus	<b>3</b>	<b>0</b>	<b>2</b>
Hyperglycaemia	<b>2</b>	<b>0</b>	<b>1</b>

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Case Group	Death Outcomes	Sole
Hypoglycaemia	<b>1</b>	<b>0</b>
Hypercholesterolaemia	<b>3</b>	<b>0</b>
Hypoalbuminaemia	<b>1</b>	<b>0</b>
Hipoproteinaemia	<b>1</b>	<b>0</b>
Gout	<b>1</b>	<b>0</b>
<b>Metabolism and nutrition disorders</b>	<b>289</b>	<b>6</b>
		<b>163</b>
Osteomalacia	<b>1</b>	<b>0</b>
Osteoporosis	<b>4</b>	<b>0</b>
Collagen disorder	<b>1</b>	<b>0</b>
Systemic lupus erythematosus	<b>9</b>	<b>0</b>
Pathological fracture	<b>1</b>	<b>0</b>
Arthritis	<b>6</b>	<b>0</b>
Arthropathy	<b>2</b>	<b>0</b>
Haemarthrosis	<b>1</b>	<b>0</b>
Arthralgia	<b>37</b>	<b>0</b>
Joint swelling	<b>2</b>	<b>0</b>
Osteoarthritis	<b>2</b>	<b>0</b>
Myositis	<b>5</b>	<b>0</b>
Myalgia	<b>43</b>	<b>0</b>
Muscle spasms	<b>6</b>	<b>0</b>
Muscle tightness	<b>1</b>	<b>0</b>
Muscle twitching	<b>5</b>	<b>0</b>
Muscle rigidity	<b>1</b>	<b>0</b>
Muscular weakness	<b>1</b>	<b>0</b>
Dupuytren's contracture	<b>1</b>	<b>0</b>
Mobility decreased	<b>1</b>	<b>0</b>
Musculoskeletal stiffness	<b>2</b>	<b>0</b>
Back pain	<b>7</b>	<b>0</b>
Limb discomfort	<b>1</b>	<b>0</b>
Neck pain	<b>3</b>	<b>0</b>
Pain in extremity	<b>4</b>	<b>0</b>
Tendonitis	<b>2</b>	<b>0</b>

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Reaction Count		Case Group	Death Outcomes	Sole	
	Musculoskeletal and connective tissue disorders	<b>Musculoskeletal and connective tissue disorders</b>	<b>149</b>	<b>0</b>	<b>109</b>
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	1	0	1
		Pseudolymphoma	4	0	4
		Benign hepatic neoplasm	2	0	1
		Myelodysplastic syndrome	1	0	0
		Lymphoma	1	0	0
		Teratoma	1	0	1
		<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>	<b>10</b>	<b>0</b>	<b>7</b>
	Nervous system disorders	Encephalitis	1	0	1
		Cerebral haemorrhage	2	0	0
		Cerebral haemorrhage neonatal	1	0	0
		Cerebrovascular disorder	1	0	0
		Transient ischaemic attack	1	0	0
		Anosmia	1	0	1
		Parosmia	1	0	1
		Optic neuritis	1	0	1
		Trigeminal neuralgia	2	0	2
		Encephalopathy	7	0	1
		Hypoxic-ischaemic encephalopathy	1	1	0
		Headache	100	2	73
		Migraine	4	0	3
		Brain oedema	2	2	0
		Intracranial pressure increased	2	1	1
		Dementia	3	0	1
		Amnesia	9	0	4
		Memory impairment	1	0	0
		Disturbance in attention	7	0	3
		Mental impairment	1	0	0
		Choreoathetosis	6	0	5
		Clumsiness	1	0	1
		Dyskinesia	6	0	3
		Extrapyramidal disorder	3	0	2

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Case Group	Death Outcomes	Sole
Hypokinesia	4	0
Psychomotor hyperactivity	1	0
Dystonia	1	0
Opisthotonus	2	0
Locked-in syndrome	1	0
Paralysis	2	0
Paresis	4	0
Cogwheel rigidity	1	0
Parkinsonism	1	0
Tremor	22	0
Ataxia	96	0
Balance disorder	4	0
Cerebellar syndrome	3	0
Coordination abnormal	13	0
Dysstasia	2	0
Nystagmus	25	0
Coma	15	0
Aphasia	8	0
Altered state of consciousness	1	0
Consciousness fluctuating	6	0
Lethargy	22	0
Loss of consciousness	2	0
Sedation	3	0
Somnolence	85	0
Stupor	2	0
Syncope	13	2
Nervous system disorder	1	0
Dizziness	76	0
Drooling	1	0
Head discomfort	1	0
Meningism	3	0
Presyncope	1	0
Burning sensation	2	0

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Case Group	Death Outcomes	Sole
Paraesthesia	<b>18</b>	0
Ageusia	3	0
Dysgeusia	8	0
Hypoesthesia	<b>10</b>	0
Neuralgia	4	0
Sensory disturbance	1	0
Dysarthria	<b>12</b>	0
Speech disorder	<b>14</b>	0
Visual field defect	<b>19</b>	0
Horner's syndrome	1	0
Upper motor neurone lesion	1	0
Hypertonia	<b>9</b>	0
Hypotonia	1	0
Neuroleptic malignant syndrome	1	0
Carpal tunnel syndrome	1	0
Neuropathy peripheral	3	0
Petit mal epilepsy	1	0
Grand mal convulsion	<b>11</b>	1
Complex partial seizures	1	0
Convulsion	<b>90</b>	5
Drug withdrawal convulsions	1	0
Epilepsy	1	0
Tonic convulsion	1	0
Hypersomnia	1	0
<b>Nervous system disorders</b>	<b>801</b>	<b>14</b>
		<b>423</b>
Pregnancy, puerperium and perinatal conditions		
Abortion spontaneous	4	0
Intra-uterine death	5	1
Stillbirth	1	0
Foetal growth restriction	3	0
Delayed delivery	1	0
Ectopic pregnancy	2	0
Premature baby	1	0
Jaundice neonatal	2	0
		2

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Case Group	Death Outcomes	Sole
Neonatal disorder	<b>1</b>	<b>0</b>
Polyhydramnios	<b>1</b>	<b>1</b>
Pregnancy with implant contraceptive	<b>4</b>	<b>0</b>
Unintended pregnancy	<b>43</b>	<b>0</b>
<b>Pregnancy, puerperium and perinatal conditions</b>	<b>68</b>	<b>2</b>
Agitation	<b>21</b>	<b>0</b>
Anxiety	<b>6</b>	<b>0</b>
Nervousness	<b>8</b>	<b>0</b>
Obsessive-compulsive disorder	<b>1</b>	<b>0</b>
Catatonia	<b>2</b>	<b>0</b>
Restlessness	<b>1</b>	<b>0</b>
Head banging	<b>1</b>	<b>0</b>
Logorrhoea	<b>1</b>	<b>0</b>
Confusional state	<b>81</b>	<b>0</b>
Disorientation	<b>3</b>	<b>0</b>
Delirium	<b>5</b>	<b>0</b>
Depression	<b>11</b>	<b>0</b>
Depressed mood	<b>1</b>	<b>0</b>
Psychomotor retardation	<b>1</b>	<b>0</b>
Depersonalisation	<b>4</b>	<b>0</b>
Delusion	<b>3</b>	<b>0</b>
Hallucination	<b>18</b>	<b>0</b>
Hallucination, visual	<b>1</b>	<b>0</b>
Bradyphrenia	<b>1</b>	<b>0</b>
Thinking abnormal	<b>7</b>	<b>0</b>
Eating disorder	<b>1</b>	<b>0</b>
Bipolar disorder	<b>1</b>	<b>0</b>
Mania	<b>5</b>	<b>0</b>
Affect lability	<b>2</b>	<b>0</b>
Emotional distress	<b>1</b>	<b>0</b>
Euphoric mood	<b>2</b>	<b>0</b>
Mood altered	<b>2</b>	<b>0</b>

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Case Group	Death Outcomes	Sole
Mood swings	<b>1</b>	<b>0</b>
Apathy	<b>3</b>	<b>0</b>
Aggression	<b>12</b>	<b>0</b>
Grandiosity	<b>1</b>	<b>0</b>
Paranoia	<b>3</b>	<b>0</b>
Personality disorder	<b>2</b>	<b>0</b>
Abnormal behaviour	<b>2</b>	<b>0</b>
Hypervigilance	<b>1</b>	<b>0</b>
Mental status changes	<b>1</b>	<b>0</b>
Withdrawal syndrome	<b>5</b>	<b>0</b>
Acute psychosis	<b>1</b>	<b>0</b>
Psychotic disorder	<b>7</b>	<b>0</b>
Libido decreased	<b>5</b>	<b>0</b>
Insomnia	<b>9</b>	<b>0</b>
Abnormal dreams	<b>1</b>	<b>0</b>
Nightmare	<b>7</b>	<b>0</b>
Sleep disorder	<b>2</b>	<b>0</b>
Polydipsia psychogenic	<b>1</b>	<b>0</b>
Completed suicide	<b>1</b>	<b>1</b>
Suicidal ideation	<b>1</b>	<b>0</b>
Suicide attempt	<b>2</b>	<b>0</b>
<b>Psychiatric disorders</b>	<b>259</b>	<b>1</b>
	<b>134</b>	
Bladder dilatation	<b>1</b>	<b>0</b>
Glomerulonephritis	<b>2</b>	<b>0</b>
Nephrotic syndrome	<b>1</b>	<b>0</b>
Tubulointerstitial nephritis	<b>4</b>	<b>0</b>
Renal tubular acidosis	<b>1</b>	<b>0</b>
Oliguria	<b>4</b>	<b>0</b>
Renal failure	<b>1</b>	<b>0</b>
Renal failure acute	<b>14</b>	<b>0</b>
Renal impairment	<b>11</b>	<b>0</b>
Urethral obstruction	<b>1</b>	<b>0</b>
Dysuria	<b>6</b>	<b>0</b>

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Reaction Count			Case Group	Death Outcomes	Sole
Renal and urinary disorders	Micturition disorder	3	0	1	
	Micturition urgency	1	0	1	
	Pollakiuria	7	0	4	
	Urinary incontinence	8	0	5	
	Urinary retention	9	0	4	
	Albuminuria	5	0	5	
	Chromaturia	3	0	2	
	Haematuria	11	0	9	
	Nocturia	2	0	2	
	Polyuria	5	0	5	
	Renal pain	4	0	2	
	Nephrolithiasis	2	0	0	
	<b>Renal and urinary disorders</b>	<b>106</b>	<b>0</b>	<b>60</b>	
Reproductive system and breast disorders	Breast enlargement	1	0	1	
	Gynaecomastia	7	0	4	
	Breast engorgement	1	0	0	
	Breast pain	1	0	1	
	Galactorrhoea	5	0	3	
	Balanoposthitis	1	0	1	
	Menstrual disorder	2	0	1	
	Menstruation irregular	2	0	1	
	Metrorrhagia	2	0	0	
	Amenorrhoea	3	0	2	
	Menstruation delayed	1	0	1	
	Menorrhagia	3	0	2	
	Scrotal oedema	1	0	0	
	Genital ulceration	7	0	2	
	Pelvic pain	1	0	0	
	Ejaculation failure	1	0	0	
	Erectile dysfunction	6	0	5	
	Vaginal haemorrhage	3	0	0	
	Vulval ulceration	1	0	1	
	<b>Reproductive system and breast disorders</b>	<b>49</b>	<b>0</b>	<b>25</b>	

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Case Group	Death Outcomes	Sole
Bronchospasm	4	0
Wheezing	1	0
Eosinophilic pneumonia	1	0
Pneumonitis	1	0
Lung infiltration	5	0
Pulmonary oedema	1	0
Neonatal respiratory distress syndrome	1	0
Pleural effusion	3	0
Pulmonary embolism	5	0
Apnoea	1	0
Dyspnoea	27	1
Dyspnoea paroxysmal nocturnal	1	0
Hyperventilation	1	0
Orthopnoea	1	0
Respiratory depression	1	0
Respiratory distress	2	0
Hypoxia	5	0
Cough	24	0
Haemoptysis	1	0
Hiccups	2	0
Respiratory disorder	1	0
Respiratory tract irritation	1	0
Dry throat	1	0
Oropharyngeal blistering	1	0
Oropharyngeal pain	10	0
Stridor	1	0
Epistaxis	6	0
<b>Respiratory, thoracic and mediastinal disorders</b>	<b>109</b>	<b>1</b>
<b>Skin and subcutaneous tissue disorders</b>	<b>1</b>	<b>73</b>
Angioedema	5	0
Urticaria	59	0
Lichenoid keratosis	6	0
Skin atrophy	1	0

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Case Group	Death Outcomes	Sole	
Blister	<b>8</b>	<b>0</b>	<b>8</b>
Dermatitis bullous	<b>18</b>	<b>0</b>	<b>10</b>
Erythema multiforme	<b>23</b>	<b>0</b>	<b>17</b>
Stevens-Johnson syndrome	<b>75</b>	<b>1</b>	<b>53</b>
Toxic epidermal necrolysis	<b>17</b>	<b>1</b>	<b>11</b>
Dermatosis	<b>1</b>	<b>0</b>	<b>1</b>
Dry skin	<b>1</b>	<b>0</b>	<b>1</b>
Pain of skin	<b>1</b>	<b>0</b>	<b>0</b>
Skin burning sensation	<b>1</b>	<b>0</b>	<b>1</b>
Skin discolouration	<b>7</b>	<b>0</b>	<b>4</b>
Skin fissures	<b>1</b>	<b>0</b>	<b>0</b>
Skin reaction	<b>1</b>	<b>0</b>	<b>1</b>
Swelling face	<b>4</b>	<b>0</b>	<b>3</b>
Dermatitis	<b>9</b>	<b>0</b>	<b>6</b>
Eczema	<b>6</b>	<b>0</b>	<b>6</b>
Drug eruption	<b>2</b>	<b>0</b>	<b>1</b>
Drug rash with eosinophilia and systemic symptoms	<b>8</b>	<b>0</b>	<b>7</b>
Erythema	<b>6</b>	<b>0</b>	<b>2</b>
Generalised erythema	<b>2</b>	<b>0</b>	<b>1</b>
Rash erythematous	<b>133</b>	<b>1</b>	<b>94</b>
Dermatitis exfoliative	<b>28</b>	<b>0</b>	<b>22</b>
Exfoliative rash	<b>4</b>	<b>0</b>	<b>2</b>
Skin exfoliation	<b>31</b>	<b>0</b>	<b>22</b>
Necrobiosis lipoidica diabetorum	<b>1</b>	<b>0</b>	<b>0</b>
Interstitial granulomatous dermatitis	<b>1</b>	<b>0</b>	<b>1</b>
Rash papular	<b>2</b>	<b>0</b>	<b>2</b>
Photosensitivity reaction	<b>36</b>	<b>0</b>	<b>28</b>
Pruritus	<b>218</b>	<b>0</b>	<b>153</b>
Rash pruritic	<b>7</b>	<b>0</b>	<b>4</b>
Dermatitis psoriasiform	<b>4</b>	<b>0</b>	<b>3</b>
Psoriasis	<b>2</b>	<b>0</b>	<b>2</b>
Acute generalised exanthematous pustulosis	<b>1</b>	<b>0</b>	<b>1</b>
Fixed eruption	<b>1</b>	<b>0</b>	<b>0</b>

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

			Case Group	Death Outcomes	Sole
Reaction Count	Skin and subcutaneous tissue disorders	Rash	<b>270</b>	<b>0</b>	<b>196</b>
		Rash generalised	<b>8</b>	<b>0</b>	<b>5</b>
		Rash macular	<b>6</b>	<b>0</b>	<b>5</b>
		Rash maculo-papular	<b>238</b>	<b>0</b>	<b>159</b>
		Rash morbilliform	<b>43</b>	<b>0</b>	<b>30</b>
		Rash vesicular	<b>2</b>	<b>0</b>	<b>1</b>
		Systemic lupus erythematosus rash	<b>4</b>	<b>0</b>	<b>4</b>
		Decubitus ulcer	<b>1</b>	<b>0</b>	<b>1</b>
		Lentigo	<b>1</b>	<b>0</b>	<b>1</b>
		Penile ulceration	<b>1</b>	<b>0</b>	<b>1</b>
		Skin ulcer	<b>2</b>	<b>0</b>	<b>0</b>
		Acne	<b>2</b>	<b>0</b>	<b>2</b>
		Alopecia	<b>19</b>	<b>0</b>	<b>11</b>
		Cold sweat	<b>3</b>	<b>0</b>	<b>2</b>
		Hyperhidrosis	<b>53</b>	<b>0</b>	<b>41</b>
		Night sweats	<b>4</b>	<b>0</b>	<b>2</b>
		Sweat gland disorder	<b>1</b>	<b>0</b>	<b>0</b>
		Hirsutism	<b>2</b>	<b>0</b>	<b>2</b>
		Hypertrichosis	<b>2</b>	<b>0</b>	<b>2</b>
		Nail disorder	<b>1</b>	<b>0</b>	<b>0</b>
		Hair colour changes	<b>1</b>	<b>0</b>	<b>0</b>
		Petechiae	<b>4</b>	<b>0</b>	<b>2</b>
		Purpura	<b>39</b>	<b>2</b>	<b>25</b>
		Leukocytoclastic vasculitis	<b>2</b>	<b>0</b>	<b>2</b>
		Livedo reticularis	<b>1</b>	<b>0</b>	<b>0</b>
		<b>Skin and subcutaneous tissue disorders</b>	<b>1441</b>	<b>5</b>	<b>1008</b>
Social circumstances	Social circumstances	Treatment noncompliance	<b>1</b>	<b>0</b>	<b>0</b>
		<b>Social circumstances</b>	<b>1</b>	<b>0</b>	<b>0</b>
Surgical and medical procedures	Surgical and medical procedures	Drug therapy changed	<b>2</b>	<b>0</b>	<b>2</b>
		Therapy regimen changed	<b>16</b>	<b>0</b>	<b>10</b>
Vascular disorders	Vascular disorders	<b>Surgical and medical procedures</b>	<b>18</b>	<b>0</b>	<b>12</b>
		Blood pressure fluctuation	<b>1</b>	<b>0</b>	<b>1</b>
		Circulatory collapse	<b>6</b>	<b>0</b>	<b>2</b>

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)

## **Medicine summary - Antipsychotics- carbamazepine**

Reaction Count	Vascular disorders		Case Group	Death Outcomes	Sole
	Hypotension		17	0	10
	Orthostatic hypotension		4	0	2
	Thrombosis		2	1	1
	Deep vein thrombosis		1	0	1
	Thrombophlebitis superficial		2	0	2
	Vasodilatation		1	0	1
	Vein pain		1	0	1
	Flushing		7	0	6
	Hot flush		2	0	1
	Pallor		3	0	2
	Haematoma		1	0	0
	Haemorrhage		1	0	1
	Hypertension		6	0	5
	Vasculitis		6	0	6
	<b>Vascular disorders</b>		<b>61</b>	<b>1</b>	<b>42</b>
	<b>Reaction</b>		<b>6316</b>	<b>105</b>	<b>3867</b>

 Rows are suppressed based on zeros and empty cells for Case Group

 [Outcome Description](#)

 [\(Causality possible,Causality probable,Causality certain\)](#)

 [Suspect Type](#)

 [Suspect Code](#)

 [Case Group](#)

 [GM](#)

 [Carbamazepine](#)